Evidence map›Paper›PMID 32356150›Full record

ArticleJournal of neuro-oncology2020

Role of VHL-JAK-STAT signaling pathway in central nervous system hemangioblastoma associated with von Hippel-Lindau disease.

Hiroshi Kanno, Tetsuya Yoshizumi, Masamichi Shinonaga, Atsuhiko Kubo, Hidetoshi Murata, Masahiro Yao

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Von Hippel-Lindau/Hypoxia Inducible Factor Axis in Glioblastoma.International journal of molecular sciences · 2025
    Review
  2. Review
  3. Article
  4. Role of SOCS and VHL Proteins in Neuronal Differentiation and Development.International journal of molecular sciences · 2023
    Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Hiroshi KannoDepartment of Neurosurgery, International University of Health and Welfare Atami Hospital, 13-1 Higashikaigan-cho, Atami, Shizuoka, 413-0012, Japan. hiroshikannomd@nifty.com.ORCID http://orcid.org/0000-0002-4335-3899
Tetsuya YoshizumiDepartment of Neurosurgery, International University of Health and Welfare Atami Hospital, 13-1 Higashikaigan-cho, Atami, Shizuoka, 413-0012, Japan.
Masamichi ShinonagaDepartment of Neurosurgery, International University of Health and Welfare Atami Hospital, 13-1 Higashikaigan-cho, Atami, Shizuoka, 413-0012, Japan.
Atsuhiko KuboDepartment of Neurosurgery, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.
Hidetoshi MurataDepartment of Neurosurgery, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.
Masahiro YaoDepartment of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.
International University Of Health And Welfare Atami Hospital · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCentral nervous system hemangioblastoma is a benign tumor associated with or without von Hippel-Lindau (VHL) disease which is an autosomal dominant hereditary disease that results from a germline mutation in the VHL gene. A main axis of signaling pathways in central nervous system hemangioblastoma is VHL-HIF signaling pathway. Here, we propose an alternative VHL-JAK-STAT signaling pathway in hemangioblastoma and discuss the role.

methodsUsing MACS method, Scl

resultsJAK2 and STAT3 in Scl

Indexed as

Signal TransductionAdultCerebellar NeoplasmsFemaleHemangioblastomaHumansJanus Kinase 2MutationSTAT3 Transcription Factorvon Hippel-Lindau DiseaseVon Hippel-Lindau Tumor Suppressor ProteinYoung AdultJAK2 protein, humanJanus Kinase 2STAT3 protein, humanSTAT3 Transcription FactorVHL protein, humanVon Hippel-Lindau Tumor Suppressor ProteinHemangioblastoma.JAK-STAT pathwayVHLvon Hippel-Lindau disease

Identifiers

PMID32356150
OpenAlexW3022646851

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.